Antibiotics

Through policy and fostering innovation, the Biotechnology Innovation Organization (BIO) is working towards reducing antimicrobial resistance (AMR).

Patient advocate Ella Balasa has been living with cystic fibrosis her whole life. She experienced a multidrug resistant infection in 2019 and is speaking about her personal experiences at the World AMR Congress reminding people about the need to improve the antibiotic development paradigm.

In preclinical studies, the antimicrobial, clovibactin, was shown to have susceptibility against a broad spectrum of pathogens and also worked against a specific bacteria in 2 animal studies.

With an increased incidence of this sexually transmitted infection, a review of an older antibiotic for treatment has shown some clinical benefits in other countries.

This is a challenging pathogen, requiring pharmacokinetic and pharmacodynamic considerations; the recent FDA approval of sulbactam-durlobactam offers new hope.

With potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.

The Prescription Drug User Fee Act (PDUFA) action date is scheduled for the first quarter of 2024.

Patients with a penicillin allergy can be safely delabeled using minimal resources, opening up treatment options.

For patients undergoing surgery, looking at the potential benefits of this antimicrobial for prophylaxis.

This conference is addressing antimicrobial resistance (AMR) from different perspectives and look at strategies to reduce this global health problem.

A new study finds antimicrobial resistance (AMR) evolves rapidly in patients colonized by diverse P aeruginosa populations due to selection for preexisting resistant strains, demonstrating a clear link between within-host diversity and resistance.

Although the literature and science may change, hanging onto beliefs about therapeutics is a tradition passed down from instructors to learners. A change in this paradigm may be warranted.

This long-time, understudied virus, can fight bacterial infections and may be poised to become an important treatment option in western medicine.

Trial of standard vs short course antimicrobial treatment of uncomplicated UTI in children favors standard, but with caveat for early responders.

Five organizations have updated the 2014 compendium, "Strategies to Prevent Methicillin-Resistant Staphylococcus aureus Transmission and Infection in Acute Care Hospitals." In doing so, they have elevated antimicrobial stewardship from an “additional practice” to an “essential practice.”

Penicillin allergy is not uncommon, but its occurrence is exaggerated by erroneous allergy labeling that unnecessarily precludes treatment options.

The Outpatient Automated Stewardship Information System (OASIS) is a platform that allows clinicians the ability to improve their prescribing practices in hopes of delivering a more judicious approach and moving towards stewardship.

The strategy for administering beta-lactam antibiotics for treating critically ill patients with sepsis showed no clinical difference in a study of continuous versus intermittent administration of meropenem.

Though the drug is initially more expensive, treating C diff infection with fidaxomicin reduced costs overall by reducing CDI recurrences.

The federal agency explains this increase in 2022 was substantial compared to previous years, and recommends this population be up-to-date on vaccines for it.

With an estimated 30% of Americans living with a tattoo, the federal agency has developed guidance designed to give manufacturers information and resources to prevent potential health issues.

In phase 3 studies, the company’s investigational therapy, aztreonam-avibactam (ATM-AVI), had favorable results over other treatments used for complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).

As the first line of acute care, emergency departments are key stewards of antibiotics.

So far, the Virginia Mason Medical Center in Seattle has confirmed 33 patients have been infected with Klebsiella pneumoniae bacteria, 9 of whom have died.

Rates of hospital-onset multidrug-resistant P aeruginosa infections have increased significantly in recent years.